Logo image of ONCO

ONCONETIX INC (ONCO) Stock Fundamental Analysis

NASDAQ:ONCO - Nasdaq - US68237Q1040 - Common Stock - Currency: USD

0.088  +0.01 (+8.37%)

Premarket: 0.0856 0 (-2.73%)

Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to ONCO. ONCO was compared to 561 industry peers in the Biotechnology industry. ONCO has a bad profitability rating. Also its financial health evaluation is rather negative. ONCO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ONCO has reported negative net income.
ONCO had a negative operating cash flow in the past year.
ONCO had negative earnings in each of the past 5 years.
In the past 5 years ONCO always reported negative operating cash flow.
ONCO Yearly Net Income VS EBIT VS OCF VS FCFONCO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -83.34%, ONCO is doing worse than 71.84% of the companies in the same industry.
ONCO has a Return On Equity of -152.17%. This is in the lower half of the industry: ONCO underperforms 64.17% of its industry peers.
Industry RankSector Rank
ROA -83.34%
ROE -152.17%
ROIC N/A
ROA(3y)-75.1%
ROA(5y)-57.66%
ROE(3y)-134.27%
ROE(5y)-93.36%
ROIC(3y)N/A
ROIC(5y)N/A
ONCO Yearly ROA, ROE, ROICONCO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -50 -100 -150 -200 -250

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ONCO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ONCO Yearly Profit, Operating, Gross MarginsONCO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -20K -40K -60K

More info and screens

1

2. Health

2.1 Basic Checks

ONCO does not have a ROIC to compare to the WACC, probably because it is not profitable.
ONCO has less shares outstanding than it did 1 year ago.
ONCO has a worse debt/assets ratio than last year.
ONCO Yearly Shares OutstandingONCO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 5M 10M 15M
ONCO Yearly Total Debt VS Total AssetsONCO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -3.04, we must say that ONCO is in the distress zone and has some risk of bankruptcy.
ONCO has a Altman-Z score of -3.04. This is comparable to the rest of the industry: ONCO outperforms 48.31% of its industry peers.
ONCO has a Debt/Equity ratio of 0.29. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.29, ONCO is not doing good in the industry: 71.66% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF N/A
Altman-Z -3.04
ROIC/WACCN/A
WACC6.47%
ONCO Yearly LT Debt VS Equity VS FCFONCO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 20M 40M

2.3 Liquidity

A Current Ratio of 0.06 indicates that ONCO may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.06, ONCO is doing worse than 98.22% of the companies in the same industry.
ONCO has a Quick Ratio of 0.06. This is a bad value and indicates that ONCO is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of ONCO (0.05) is worse than 98.40% of its industry peers.
Industry RankSector Rank
Current Ratio 0.06
Quick Ratio 0.05
ONCO Yearly Current Assets VS Current LiabilitesONCO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M

More info and screens

0

3. Growth

3.1 Past

ONCO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -8438.24%.
EPS 1Y (TTM)-8438.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-845.26%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ONCO is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -14.13% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-11.84%
EPS Next 2Y-14.13%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ONCO Yearly Revenue VS EstimatesONCO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 10K 20K 30K 40K 50K
ONCO Yearly EPS VS EstimatesONCO Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 -10 -20 -30 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ONCO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ONCO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ONCO Price Earnings VS Forward Price EarningsONCO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ONCO Per share dataONCO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80

4.3 Compensation for Growth

ONCO's earnings are expected to decrease with -14.13% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.13%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ONCO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ONCONETIX INC

NASDAQ:ONCO (5/20/2025, 9:48:23 PM)

Premarket: 0.0856 0 (-2.73%)

0.088

+0.01 (+8.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-19 2025-05-19
Earnings (Next)N/A N/A
Inst Owners2.85%
Inst Owner Change-11.36%
Ins Owners8.99%
Ins Owner Change0.04%
Market Cap1.28M
Analysts43.33
Price TargetN/A
Short Float %17.33%
Short Ratio0.15
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.68
P/FCF N/A
P/OCF N/A
P/B 0.04
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-95.63
EYN/A
EPS(NY)-1.01
Fwd EYN/A
FCF(TTM)-0.96
FCFYN/A
OCF(TTM)-0.95
OCFYN/A
SpS0.13
BVpS2.33
TBVpS-1.81
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -83.34%
ROE -152.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-75.1%
ROA(5y)-57.66%
ROE(3y)-134.27%
ROE(5y)-93.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.48%
Cap/Sales 1.57%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.06
Quick Ratio 0.05
Altman-Z -3.04
F-Score3
WACC6.47%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8438.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-845.26%
EPS Next Y-11.84%
EPS Next 2Y-14.13%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-14.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-111.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-111.4%
OCF growth 3YN/A
OCF growth 5YN/A